CRISPR Therapeutics AG (CRSP)
53.81
+0.82
(+1.55%)
USD |
NASDAQ |
May 01, 16:00
53.81
0.00 (0.00%)
After-Hours: 17:50
CRISPR Therapeutics Shareholders Equity (Quarterly): 1.883B for Dec. 31, 2023
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 1.883B |
September 30, 2023 | 1.728B |
June 30, 2023 | 1.816B |
March 31, 2023 | 1.855B |
December 31, 2022 | 1.875B |
September 30, 2022 | 1.954B |
June 30, 2022 | 2.091B |
March 31, 2022 | 2.245B |
December 31, 2021 | 2.399B |
September 30, 2021 | 2.513B |
June 30, 2021 | 2.604B |
March 31, 2021 | 1.805B |
December 31, 2020 | 1.664B |
September 30, 2020 | 1.343B |
June 30, 2020 | 910.67M |
March 31, 2020 | 886.10M |
Date | Value |
---|---|
December 31, 2019 | 939.42M |
September 30, 2019 | 591.88M |
June 30, 2019 | 367.68M |
March 31, 2019 | 379.81M |
December 31, 2018 | 392.20M |
September 30, 2018 | 417.31M |
June 30, 2018 | 265.15M |
March 31, 2018 | 290.34M |
December 31, 2017 | 187.83M |
September 30, 2017 | 178.96M |
June 30, 2017 | 197.80M |
March 31, 2017 | 215.18M |
December 31, 2016 | 232.85M |
September 30, 2016 | -62.48M |
June 30, 2016 | 135.34M |
December 31, 2015 | -29.10M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
367.68M
Minimum
Jun 2019
2.604B
Maximum
Jun 2021
1.656B
Average
1.816B
Median
Jun 2023
Shareholders Equity (Quarterly) Benchmarks
Vertex Pharmaceuticals Inc | 17.58B |
Intellia Therapeutics Inc | 1.050B |
Novartis AG | 39.68B |
Verve Therapeutics Inc | 599.50M |
AC Immune SA | 191.25M |
Shareholders Equity (Quarterly) Related Metrics
Total Assets (Quarterly) | 2.230B |
Total Liabilities (Quarterly) | 346.77M |
Current Ratio | 17.54 |